Federal Court Dismisses Acuitas Therapeutics’ Patent Lawsuit Against Alnylam Pharmaceuticals in mRNA Technology Dispute

A federal judge in Delaware has dismissed a lawsuit filed by Acuitas Therapeutics against Alnylam Pharmaceuticals. The complaint sought to add Acuitas scientists as inventors on seven patents held by Alnylam, which are related to mRNA technology—a cornerstone in the development of COVID-19 vaccines. The court ruled that Acuitas failed to demonstrate that its scientists had a significant financial or reputational interest in the outcome of the lawsuit. For more details on the case, you can read the full report on Law360.